Concepedia

Helene D. Sabia

HD

5

Publications

198

Citations

5

H-Index

2001

Active since

Affiliations

Novartis (Switzerland)(Current)

Helene D. Sabia is an author at Novartis (Switzerland) specializing in pharmacotherapy, drug resistance, and medicine.

Top concepts

Publications per year

2001–2020

5

Publications

5

Influence of hepatic impairment on everolimus pharmacokinetics: Implications for dose adjustment

John M. Kovarik, Helene D. Sabia, Joaquim Figueiredo et al. · Clinical Pharmacology & Therapeutics · 2001 · 95 citations

Safety, Tolerability, and Pharmacokinetics of an Extended-Release Formulation of Fluvastatin Administered Once Daily to Patients with Primary Hypercholesterolemia

Helene D. Sabia, Pratapa Prasad, Harold T. Smith et al. · Journal of Cardiovascular Pharmacology · 2001 · 41 citations

Efficacy and safety of TS-121, a novel vasopressin V1B receptor antagonist, as adjunctive treatment for patients with major depressive disorder: A randomized, double-blind, placebo-controlled study

Makoto Kamiya, Helene D. Sabia, Julie Marella et al. · Journal of Psychiatric Research · 2020 · 27 citations · Full text

Bioequivalence of vildagliptin/metformin fixed-dose combination tablets and a free combination of vildagliptin and metformin in healthy subjects

Yanling He, Stefanía Paladini, Helene D. Sabia et al. · International Journal of Clinical Pharmacology and Therapeutics · 2008 · 18 citations

Effect of a selective CYP2C9 inhibitor on the pharmacokinetics of nateglinide in healthy subjects

Helene D. Sabia, Gangadhar Sunkara, Monica Ligueros‐Saylan et al. · European Journal of Clinical Pharmacology · 2004 · 17 citations

, , +5

Rows per page

1–5 of 5